RESTORE 2 INTERIM 6 MONTH RESULTS

Interim results from a European clinical trial, RESTORE 2, demonstrate that cell-enriched breast reconstruction achieved a high rate of patient and physician satisfaction and improvements in overall breast deformity in lumpectomy patients. These results are based on six-month follow up from the first 32 women enrolled and treated. The results were presented at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by Dr. Eva Weiler-Mithoff, M.D., co-principal investigator for the Restore 2 Trial at the Glasgow Royal Infirmary.
>>View SABCS poster.

The highlights from the interim data of Cytori Therapeutics’ RESTORE 2 clinical trial include:
  • A high rate of patient satisfaction (73%) and physician satisfaction (82%) with the overall outcome after a single treatment was reported in difficult to treat breast cancer patients
  • Mean patient and physician satisfaction scores dramatically improved for breast symmetry, scarring and deformity from baseline to six month follow-up
  • Qualitative analyses of imaging data confirmed clinical improvement in both breast defect and overall breast shape
>> Learn More: Cytori’s press release detailing interim RESTORE 2 results
Bookmark and Share